As of May 24, 2025, Onconova Therapeutics Inc (ONTX) reports a EV/EBITDA of 0.22.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Onconova Therapeutics Inc's EV/EBITDA to Peers
To better understand Onconova Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Onconova Therapeutics Inc (ONTX) | 0.22 |
| Bristol-Myers Squibb Co (BMY) | 50.49 |
| Catalent Inc (CTLT) | 45.03 |
| Eli Lilly and Co (LLY) | 43.75 |
| Zoetis Inc (ZTS) | 20.03 |
| Johnson & Johnson (JNJ) | 13.88 |
Compared to its competitors, Onconova Therapeutics Inc's EV/EBITDA is about average compared to peers, indicating market valuation in line with industry expectations.